Although T315I BCR-ABL is sufficient to confer resistance to TKIs in CML cells, surprisingly we found that multiple drug resistance pathways were activated in KCL-22M cells along with reduced expression of a set of myeloid differentiation genes. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.